Mifepristone is under clinical development by Corcept Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Mifepristone’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 04 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mifepristone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Mifepristone overview

Mifepristone (Korlym) is a synthetic steroid with anti-progestational effects, acts as a contraceptive agent. It is formulated as tablets for oral route of administration. Korlym is indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Mifepristone is under development for the treatment of metastatic non-small cell lung cancer, metastatic castration-resistant prostate cancer, ovarian cancer,central serous chorioretinopathy and alcohol use disorder. It is also under development for the treatment of triple negative breast cancer in combination with nab-paclitaxel and HER2 negative breast cancer in combination with pembrolizumab.

It was also under development for the treatment of psychotic major depression, Alzheimer's disease, endogenous Cushing’s syndrome and antipsychotic-induced weight gain.

Corcept Therapeutics overview

Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder, among others. Corcept is headquartered in Menlo Park, California, the US.

Quick View Mifepristone LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Mifepristone
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.